Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Program: Scientific Session
General Topic: Clinical

Clinical Year in Preview

Wednesday, October 29, 2025
10:00 AM – 11:00 AM Central Time

    Moderator(s)

  • Janet Pope, MD, FRCPC, MPH

    University of Western Ontario
    London, ON, Canada

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer-Ingelheim: Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Horizon: Advisor or Review Panel Member (Ongoing); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sandoz: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sanofi: Consultant (Ongoing); Therakos: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zura: Consultant (Ongoing)

  • MO

    Mohammed Osman, MD, PhD, BSc

    University of Alberta
    Edmonton, Alberta, Canada

    Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing); Boehringer Ingelheim: Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Therakos: Advisor or Review Panel Member (Ongoing)

    • Session Coordinator(s)

  • Janet Pope, MD, FRCPC, MPH

    University of Western Ontario
    London, ON, Canada

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer-Ingelheim: Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Horizon: Advisor or Review Panel Member (Ongoing); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sandoz: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sanofi: Consultant (Ongoing); Therakos: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zura: Consultant (Ongoing)

This popular session is on the last day of ACR Convergence 2025 and will sum up various presentations/abstracts that will predict changes in rheumatology research or practice over the next year.

Learning Objectives:

  • Apply recent knowledge from ACR Convergence 2025 that could change your practice
  • Consider how new data will shape research in rheumatic diseases

Presentations:

  • 10:00 AM – 10:30 AM Central Time
    Top Abstracts That Will Change My Practice in the Near Future

    Speaker: Laura Coates, MD, PhD – University of Oxford

  • 10:30 AM – 11:00 AM Central Time
    Abstracts That Will Shape Research in the Near Future

    Speaker: Tomas Mustelin, MD, PhD – University of Washington